CIK 0001662774
- Non-accelerated filer
- Smaller reporting company
IRulya Therapeutics Inc.
Sign in to watch- Ticker
- IRLA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 901024039
- Phone
- +1 203-208-8994
- Business address
- 101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510
- Former names
- Quince Therapeutics, Inc., Cortexyme, Inc.
- 4/A Grant or award Chief Business Officer acquired 113,569 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 64,589 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Chief Medical Officer acquired 24,336 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Director acquired 519,283 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Director acquired 200,002 shares (grant or award)
- 4 Grant or award Chief Business Officer acquired 16,224 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Chief Accounting Officer & VP acquired 34,000 shares (grant or award)
- 4 Grant or award Chief Legal & Adm. Officer acquired 140,000 shares (grant or award)
- 4 Grant or award Interim CEO, COO & CFO acquired 175,000 shares (grant or award)
- 4 Grant or award EVP, Preclinical Development acquired 155,500 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 140,000 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 6 of 11 · 211 filings